<DOC>
	<DOCNO>NCT02577341</DOCNO>
	<brief_summary>This Phase II randomize study determine efficacy toxicity Nimotuzumab combine chemoradiotherapy unresectable , local advance squamous cell lung cancer .</brief_summary>
	<brief_title>Nimotuzumab Combined With Chemoradiotherapy Unresectable Locally Advanced Squamous Cell Lung Cancer</brief_title>
	<detailed_description>This Phase II randomize study determine efficacy toxicity Nimotuzumab combine chemoradiotherapy unresectable , local advance squamous cell lung cancer . All patient receive five cycle weekly docetaxel cisplatin , 1 day 's duration . Thoracic RT include delivery 65 Gy 25 fraction weekday total five week . Nimotuzumab group treat five dos weekly nimotuzumab ( 200mg , IV ) combine chemoradiotherapy , placebo group treat five dos placebo . 150 patient need enrol 80 % power detect improvement overall survival 15 month 25 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically confirm squamous cell lung cancer patient measurable evaluable lesion base Response Evaluation Criteria Solid Tumors ( RECIST ) criteria unresectable phase IIIA ( N2 ) IIIB lung cancer confirm CT MRI ECOG performance status 01 Previously treat chemotherapy treatmentnaive previous chest radiotherapy , immunotherapy biotherapy . hemoglobin≥10 mg/dL , platelet≥100000/μL , absolute neutrophil count ≥1500/μL serum creatinine ≤1.25 time upper normal limit ( UNL ) , creatinine clearance≥60 ml/min bilirubin ≤1.5 time UNL , AST（SGOT）≤2.5 time UNL , ALT（SGPT）≤2.5 time UNL , alkaline phosphatase ≤5 time UNL FEV1 &gt; 0.8 L CB6 within normal limit patient family sign informed consent adenosquamous carcinoma previous recent another malignancy , except nonmelanoma skin cancer cervical cancer situ contraindication chemotherapy woman pregnancy , lactation period , pregnancy test 14 day first dose woman probability pregnancy without contraception tendency hemorrhage clinical trial within 30 day addict drug alcohol , AIDS patient uncontrollable seizure psychotic patient without selfcontrol ability severe allergy idiosyncrasy suitable study judge researcher</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Nimotuzumab , Chemoradiotherapy , Squamous Cell Lung Cancer</keyword>
</DOC>